A Study of Avastin (Bevacizumab) and Irinotecan Versus Temozolomide Radiochemistry in Patients With Glioblastoma
Status:
Completed
Trial end date:
2014-09-01
Target enrollment:
Participant gender:
Summary
This 2 arm study will compare the effect of Avastin + irinotecan versus temozolomide, in
combination with conventional involved field radiotherapy, in patients with newly diagnosed
glioblastoma and a non-methylated MGMT promoter. Patients will be randomized 3:1 to receive
Avastin 10mg/kg iv every 2 weeks + irinotecan 125mg/m2 iv every 2 weeks, or temozolomide
75mg/m2 po daily during radiotherapy followed by 6 cycles of temozolomide 150-200mg/m2 po
daily on days 1-5 of each 4 week cycle. The anticipated time on study treatment is until
disease progression, and the target sample size is 100-500 individuals.